- Home
- PRVA vs HCM Comparison
PRVA vs HCM Comparison
Compare PRVA & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRVA
- HCM
- Stock Information
- Founded
- PRVA 2007
- HCM 2000
- Country
- PRVA United States
- HCM Hong Kong
- Employees
- PRVA N/A
- HCM N/A
- Industry
- PRVA Retail: Computer Software & Peripheral Equipment
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- PRVA Technology
- HCM Health Care
- Exchange
- PRVA Nasdaq
- HCM Nasdaq
- Market Cap
- PRVA N/A
- HCM 2.5B
- IPO Year
- PRVA 2021
- HCM N/A
- Fundamental
- Price
- PRVA $23.17
- HCM $14.61
- Analyst Decision
- PRVA Strong Buy
- HCM Hold
- Analyst Count
- PRVA 16
- HCM 1
- Target Price
- PRVA $27.19
- HCM $19.00
- AVG Volume (30 Days)
- PRVA 853.3K
- HCM 122.7K
- Earning Date
- PRVA 05-08-2025
- HCM 03-19-2025
- Dividend Yield
- PRVA N/A
- HCM N/A
- EPS Growth
- PRVA N/A
- HCM N/A
- EPS
- PRVA 0.11
- HCM 0.04
- Revenue
- PRVA $1,736,390,000.00
- HCM $630,201,000.00
- Revenue This Year
- PRVA $88.96
- HCM $28.98
- Revenue Next Year
- PRVA $10.70
- HCM $20.41
- P/E Ratio
- PRVA $213.27
- HCM $71.43
- Revenue Growth
- PRVA 4.75
- HCM N/A
- 52 Week Low
- PRVA $15.92
- HCM $11.51
- 52 Week High
- PRVA $26.04
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- PRVA 48.92
- HCM 50.17
- Support Level
- PRVA $22.54
- HCM $15.00
- Resistance Level
- PRVA $23.88
- HCM $15.79
- Average True Range (ATR)
- PRVA 0.98
- HCM 0.72
- MACD
- PRVA 0.04
- HCM 0.20
- Stochastic Oscillator
- PRVA 60.21
- HCM 70.97
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.